Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Valion Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Valion Bio's ebitda for the twelve months ending Jun 30, 2025 was -$4.78M. For fiscal 2024 it was -$4.47M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$4.47M | – |
| FY2023 | Dec 31, 2023 | -$8.24M | – |
| FY2022 | Dec 31, 2022 | -$10.09M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -$1.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$298.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.43M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.24M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.11M | – |
See a number that looks wrong?